Loading clinical trials...
Loading clinical trials...
A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
Conditions
Interventions
Tislelizumab
Pamiparib
Locations
29
United States
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
February 2, 2016
Primary Completion Date
September 9, 2020
Completion Date
September 9, 2020
Last Updated
December 6, 2021
NCT04570423
NCT07177937
NCT06926283
NCT07489378
NCT07181681
NCT07387068
Lead Sponsor
BeiGene
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions